Oak Ridge Investments Lowered By $7.20 Million Its Sage Therapeutics (SAGE) Position; LEGACYXCHANGE (LEGX) Shorts Lowered By 36.36%

November 15, 2017 - By Vivian Currie

Oak Ridge Investments Llc decreased Sage Therapeutics Inc (SAGE) stake by 11.11% reported in 2017Q2 SEC filing. Oak Ridge Investments Llc sold 91,196 shares as Sage Therapeutics Inc (SAGE)’s stock rose 0.86%. The Oak Ridge Investments Llc holds 729,874 shares with $58.13M value, down from 821,070 last quarter. Sage Therapeutics Inc now has $3.31B valuation. The stock decreased 6.76% or $6.4 during the last trading session, reaching $88.25. About 10,070 shares traded. SAGE Therapeutics Inc (NASDAQ:SAGE) has risen 116.45% since November 15, 2016 and is uptrending. It has outperformed by 99.75% the S&P500.

LEGACYXCHANGE INCORPORATED (OTCMKTS:LEGX) had a decrease of 36.36% in short interest. LEGX’s SI was 3,500 shares in November as released by FINRA. Its down 36.36% from 5,500 shares previously. With 8,300 avg volume, 0 days are for LEGACYXCHANGE INCORPORATED (OTCMKTS:LEGX)’s short sellers to cover LEGX’s short positions. It closed at $0.0016 lastly. It is down 0.00% since November 15, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 16 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 14 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. SAGE Therapeutics has $145.0 highest and $18 lowest target. $94.07’s average target is 6.59% above currents $88.25 stock price. SAGE Therapeutics had 42 analyst reports since September 3, 2015 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Thursday, June 23. Cowen & Co maintained the stock with “Buy” rating in Tuesday, September 12 report. The firm has “Buy” rating by Cowen & Co given on Thursday, August 3. Chardan Capital Markets initiated SAGE Therapeutics Inc (NASDAQ:SAGE) rating on Tuesday, May 24. Chardan Capital Markets has “Sell” rating and $18 target. The stock has “Outperform” rating by Raymond James on Tuesday, September 13. On Tuesday, September 12 the stock rating was maintained by Needham with “Buy”. Raymond James upgraded the shares of SAGE in report on Wednesday, December 14 to “Strong Buy” rating. The firm earned “Buy” rating on Monday, November 14 by Stifel Nicolaus. The firm has “Buy” rating by Lake Street given on Friday, March 11. BMO Capital Markets maintained the shares of SAGE in report on Thursday, September 14 with “Outperform” rating.

Investors sentiment decreased to 0.98 in 2017 Q2. Its down 0.13, from 1.11 in 2017Q1. It fall, as 24 investors sold SAGE shares while 61 reduced holdings. 30 funds opened positions while 53 raised stakes. 37.20 million shares or 2.18% more from 36.41 million shares in 2017Q1 were reported. Federated Invsts Inc Pa stated it has 888,791 shares or 0.2% of all its holdings. Ghost Tree Capital Llc holds 0.83% or 50,000 shares in its portfolio. Deutsche National Bank & Trust Ag invested 0.04% in SAGE Therapeutics Inc (NASDAQ:SAGE). Pictet Asset Mngmt Limited reported 0.1% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). Cubist Systematic Strategies Limited Liability accumulated 3,058 shares. Ratan Cap Mngmt LP holds 1.64% or 50,000 shares. Commonwealth Of Pennsylvania School Empls Retrmt Sys has invested 0% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). Emerald Mutual Fund Advisers reported 150,273 shares. Amalgamated National Bank & Trust has 4,378 shares. Illinois-based Oak Ridge Invs Limited Liability Corp has invested 1.85% in SAGE Therapeutics Inc (NASDAQ:SAGE). 82,024 were accumulated by Bamco Inc New York. Denver Advsr Limited Co holds 4,403 shares or 0.02% of its portfolio. Bankshares Of America De reported 0% in SAGE Therapeutics Inc (NASDAQ:SAGE). Two Sigma Secs Ltd Liability Com stated it has 0.05% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). Moreover, Tocqueville Asset Mngmt LP has 0.07% invested in SAGE Therapeutics Inc (NASDAQ:SAGE).

Oak Ridge Investments Llc increased O Reilly Automotive Inc New (NASDAQ:ORLY) stake by 2,616 shares to 10,021 valued at $2.19 million in 2017Q2. It also upped Retrophin Inc Com (NASDAQ:RTRX) stake by 503,428 shares and now owns 1.02 million shares. Globus Med Inc Cl A (NYSE:GMED) was raised too.

Analysts await SAGE Therapeutics Inc (NASDAQ:SAGE) to report earnings on February, 22. They expect $-2.00 EPS, down 33.33% or $0.50 from last year’s $-1.5 per share. After $-1.97 actual EPS reported by SAGE Therapeutics Inc for the previous quarter, Wall Street now forecasts 1.52% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.